About Nordic Nanovector

Company Description

Nordic Nanovector is a leader in the development of CD37-targeted radionuclide therapies for haematological cancers.

Nordic Nanovector’s pipeline includes:
- Betalutin®, clinically safe and effective CD37-targeting radioimmunotherapy incorporating the beta emitter lutetium-177 and the murine antibody lilotomab for treatment of non-Hodgkin's lymphoma (NHL)
- Humalutin®, IND ready CD37-targeting radioimmunotherapy incorporating the beta emitter lutetium-177 and the chimeric antibody NNV003 for treatment of non-Hodgkin's lymphoma (NHL)
- 89Zr-NNV003, CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors
- Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-particle generating radionuclide lead-212,

- Multiple fully humanized anti-CD37 antibodies with different effector mechanisms for treatment of haematological cancers and autoimmune diseases

- Undisclosed discovery projects in solid tumor indications

Year founded

2009

Served area

Worldwide

Shareholder information

Shares outstanding

116,035,298

IPO

March 23, 2015

Stock exchange(s)

Euronext Oslo

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.